We retrospectively reviewed the records of 68 patients with oropharyngeal squamous cell carcinoma who had undergone initial treatment in the Department of Otolaryngology, Head and Neck Surgery, Hamanomachi Hospital between 2009 and 2017. We compared therapeutic outcomes of p16-positive with p16-negative cases, referring to Unio Internationalis Contra Cancrum（UICC）diagnostic criteria version 7 and 8. Of 68（58.5％）patients, 38 were diagnosed as p16-positive. The 3-year disease-specific survival rate of all patients, p16-positive, and p16-negative patients were 78.5％, 74.1％, and 84.7％, respectively. Referring to UICC version 8, the 3-year disease-specific survival rate（3DSS）of p16-negative patients in each clinical stage was stage Ⅱ: 100％, stageⅢ: 66.7％, and stage Ⅳa: 70.6％, whereas 3DSS of p16-positive patients was stage I: 93.8％, stageⅡ: 83.3％, stageⅢ: 77.1％, and stage Ⅳ: 0％.
All Science Journal Classification (ASJC) codes